Our Portfolio

NeuroVision Imaging, Inc.

| California, United States

NeuroVision Imaging, Inc.

| California, United States

Validation of blood based biomarkers for the detection of brain amyloid accumulation before clinical onset of dementia.

Despite the prevalence of Alzheimer's disease, the lack of an early and accurate diagnostic test remains a significant hindrance to the discovery of therapeutics. Our goal is to develop a screening tool for the early detection of Alzheimer's disease before symptoms are obvious. We have discovered proteins and metabolites in the blood that have the potential to provide an early diagnosis of Alzheimer's disease. We aim to validate the diagnostic accuracy of these biomarkers as the first steps toward more wide spread use.  We will determine the diagnostic accuracy of the biomarkers with samples from the Australian Imaging and Biomarker Lifestyle study of ageing (AIBL), which is one of the largest studies of Alzheimer's disease in the world. Overall the information gained will be a significant step forward in the development of the first approved blood test of Alzheimer’s disease.